Abstract
Coronavirus disease 2019 (COVID-19) presents as a mild-to-moderate respiratory illness in most children. However, a small proportion of children with COVID-19 develop severe or critical illnesses. Although pediatric clinical trials for the treatment of COVID-19 are sparse, some drugs are available for children and adolescents with severe COVID-19. This review summarizes clinical data focusing on antiviral agents and immunomodulators for use in treating COVID-19. In addition, current recommendations for therapeutics for children and adolescents with COVID-19 are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 1-15 |
| Number of pages | 15 |
| Journal | Pediatric Infection and Vaccine |
| Volume | 29 |
| Issue number | 1 |
| DOIs | |
| State | Published - Apr 2022 |
Bibliographical note
Publisher Copyright:© 2022 The Korean Society of Pediatric Infectious Diseases.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adolescent
- COVID-19
- Child
- Therapeutics
Fingerprint
Dive into the research topics of 'Therapeutics in the Treatment of COVID-19 for Children and Adolescents'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver